CRISPR-U™ technology (CRISPR based), developed by Ubigene, is more efficient than general
CRISPR/Cas9 technology in double-strand breaking and homologous recombination. With CRISPR-U™, Ubigene has
successfully edited over 3000 genes on more than 200 types of cell lines.
Objective
To create a Rat Senp1 Knockout
model in cell line by CRISPR-U™-mediated genome engineering.
Target gene info
Official symbol
Senp1
Gene id
300193
Organism
Rattus norvegicus
Gene type
protein-coding
Official full symbol
SUMO specific peptidase 1
Genomic regions
Chromosome 7
Strategy Summary
This gene has 3 protein coding transcripts:
Transcript ID
Name
bp
Protein
Biotype
UniProt Match
Flags
ENSRNOT00000089425.2
Senp1-203
3579
710aa
Protein coding
A0A0G2K1R8
Ensembl Canonical, APPRIS P2,
ENSRNOT00000030943.7
Senp1-201
3561
645aa
Protein coding
F1LVT6
APPRIS ALT2,
ENSRNOT00000080056.2
Senp1-202
3555
652aa
Protein coding
A0A0G2JVG1
APPRIS ALT2,
Frame-shift
Fragment A
Fragment B
gRNA Detail
Strategy
Project Comprehensive Difficulty Assessment
According to the Red Cotton database: the CRISPR gene-editing strategy design is Unknown. Knockout project comprehensive difficulty is thus assessed as Unknown.
EZ-editor™ Gene Dependency
EZ-editor™ Gene Expression Level
EZ-editor™ Gene Copy Number
EZ-editor™ Gene Dependency
Result
The Senp1 gene you inquire is evaluated as high risk
in 0%
cell line.
Cell line is not selected, unable to assess the accurate risk level, for reference only.
In all cell lines, there is
55.6% cells with low expression level,
44.4% cells with medium expression level
of Senp1 gene.
Cell line is not selected, unable to assess the accurate expression level, for reference only.
In all cell lines, there is
57.5% cells with low copy number,
37.9% cells with medium copy number,
4.6% cells with high copy number
of Senp1 gene.
Cell line is not selected, unable to assess the accurate copy number, for reference only.
Ubigene is an international high-technology enterprise focused on gene-editing cells. Our exclusive CRISPR-U™ technology has 10-20 times more efficient editing than traditional methods, easily achieving gene knockout, point mutation, and knock-in. Based on CRISPR-U™ technology, Ubigene has accumulated over 5000 successful gene-editing cases from more than 200 cell lines including iPSC and ESC, and has established a KO Cell Line Bank with 3500+ KO cell lines and Red Cotton™ gRNA Plasmid Bank with 10000+ gRNA plasmids available in stock.
Ubigene focuses on technological innovation and product development, of which EZ-editor™ series products that cover the whole workflow of gene-editing keep improving. Ubigene will move on toward our goal of "Make genome editing easier" and we won't stop!